Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
about
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, proLipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Epidemiology and management of antiretroviral-associated cardiovascular disease.Management of dyslipidemia in HIV-infected patients.Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infectionAtazanavir: its role in HIV treatmentLong-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Clinical pharmacology, efficacy and safety of atazanavir: a review.Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature.Effect of darunavir on lipid profile in HIV-infected patients.Switch strategies in antiretroviral therapy regimens.Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.Efficacy of antiretroviral therapy switch in HIV-infected patients: a 10-year analysis of the EuResist Cohort.Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
P2860
Q33729269-272FAFE2-69B1-4639-8E6B-D9909DF9160AQ34249242-B1C063ED-2B23-460D-ACD9-0D2B03A0FB5EQ34730407-00010189-52E9-4A18-A744-97745F37B4E8Q35079510-41452AE1-2B02-4A14-BEE0-EBC6599148C9Q35147189-3E25A9E7-54DE-48EC-A10B-5A90F47786E1Q35338096-03392679-37AA-4976-AC4B-905B5518D629Q35643573-65155405-67F8-4E1A-8D42-7DF815629623Q35963960-A46AC23F-D532-449A-A788-0E477C2F0CB9Q36426953-F29E43A9-1938-4A5E-896D-A22B9D061480Q36974067-CA324CD4-E4BB-4582-B345-58C703584AA1Q37249418-B87C2AC2-19FB-49EC-9C5F-FFB57BED763DQ37328870-18B5058A-EEFE-490A-AD2D-11F4B9B987D0Q37410986-D944D4F6-741C-4638-972E-5BBD29779F22Q37418140-F04A0BF3-9632-4B98-A915-4BBBE57775B4Q37622972-7DAA9CE5-B41C-4806-9A96-3351F7D94812Q37722675-BDA6CE6B-5613-4B02-84E9-960175C78EA9Q38050815-0FA6980D-889E-4533-8B54-8DBBEC341C1CQ38058385-86653DDF-DAB6-4DDC-BF2D-955BD748DB3AQ38235295-CBBD3651-C57B-48CF-9096-9345837C738CQ38813848-A4D23905-3C01-4DEF-879D-86DBF1BFA384Q38865547-2858827A-53DA-452C-8121-7530FF924258Q40617390-13EE4AC2-747E-42CD-9C9E-69A14F50EA7EQ41166201-C82022BE-FFC3-4BF6-BEE9-E922A04912D4Q42260844-27FAA468-F75D-4C47-B1DA-3BACAF9B321EQ45112147-1DCA658C-F5CC-47F4-9952-1143B81BAD6FQ45923819-FCFDAD47-AF9E-4D30-A7C0-8616802885E2Q46106006-86817211-6100-4EDF-BD73-88477805BA69Q47145824-84800710-31E7-44B2-B2EC-3E3B54D95C1DQ55698444-1FDF2153-9603-49B9-9751-21B41EB76D96Q57180790-A0382773-0801-4720-B83A-B44CE1FAB1EDQ58713369-8B944AC5-8AA9-4BF4-BD69-7F36D4BA0CAE
P2860
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@en
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@nl
type
label
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@en
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@nl
prefLabel
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@en
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@nl
P2093
P50
P1476
Efficacy and safety of switchi ...... ining HAART: the ATAZIP study.
@en
P2093
ATAZIP Study Group
Ana Cruceta
Daniel Podzamczer
David Dalmau
Elena Ferrer
Enric Pedrol
Esteban Martínez
Esteve Ribera
Félix Gutiérrez
Hernando Knobel
P356
10.1097/QAI.0B013E31819A226F
P407
P577
2009-05-01T00:00:00Z